What is juvenile idiopathic arthritis? Juvenile idiopathic arthritis (JIA) is a form of arthritis in children. Arthritis causes joint swelling (inflammation) and joint stiffness. JIA is arthritis that ...

A patient with nodular panniculitis secondary to primary myelofibrosis was successfully treated with ruxolintib and prednisone, a case study found. A case report of a patient with primary ...

Fedratinib (Inrebic) is available on the NHS. It is a possible treatment for disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential ...

The Haematological Malignancy Research Network estimate the prevalence of myelofibrosis in the UK to be 3.2 per 100,000 and the incidence is 0.6 per 100,000. This equates to 277 adults diagnosed with ...

Nag Ashwin Gets Candid On Filming Kalki 2898 I PRABHAS I DEEPIKA I AMITABH Kalki 2898 AD, a mythological sci-fi action drama directed by Nag Ashwin, marked a collaboration between Hindi and Telugu ...

Mississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or disease-related symptoms, in adult patients with intermediate or high-risk ...

Investigator-sponsored study Title: “PROMise Trial: Interim analysis of PROMise, a clinical study combining the BET inhibitor OPN-2853 with ruxolitinib in patients with advanced myelofibrosis ...

Credit: Magda Wygralak via Shutterstock. Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in adults with moderate-to-severe anaemia.

MOMENTUM was a phase III, global, multicentre, randomised, double-blind study investigating momelotinib versus danazol in patients with myelofibrosis who were symptomatic and anemic and had been ...

Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in adults with moderate-to-severe anaemia. The once-daily, oral treatment is ...

Idiopathic intracranial hypertension (IIH) affects 3.44 per 10,000 women aged 18-55 years in the United States. Significant geographic variation in cases of the condition exists, potentially ...

MOMENTUM was a phase III, global, multicentre, randomised, double-blind study investigating momelotinib versus danazol in patients with myelofibrosis who were symptomatic and anemic and had been ...